The company might finally become an oncology player.
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.